The drug lowered several types of bad fats in the pigs’ blood — including total cholesterol, LDL cholesterol, and triglycerides — by up to 31%.
Scientific Claim
Atorvastatin treatment for 21 days in miniature pigs fed a high-fat, high-cholesterol diet reduces plasma total cholesterol by 16%, LDL cholesterol by 31%, total triglyceride by 19%, and VLDL triglyceride by 28% (all P<.01).
Original Statement
“Atorvastatin treatment significantly reduced plasma total cholesterol, LDL cholesterol, total triglyceride, and VLDL triglyceride concentrations by 16%, 31%, 19%, and 28%, respectively (P<.01).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract reports observed plasma concentration changes with p-values. No causal language is used, and the phrasing matches the data.
More Accurate Statement
“Atorvastatin treatment for 21 days in miniature pigs fed a high-fat, high-cholesterol diet was associated with reductions in plasma total cholesterol by 16%, LDL cholesterol by 31%, total triglyceride by 19%, and VLDL triglyceride by 28% (all P<.01).”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bIn EvidenceThat atorvastatin directly causes reductions in plasma lipid concentrations in pigs.
That atorvastatin directly causes reductions in plasma lipid concentrations in pigs.
What This Would Prove
That atorvastatin directly causes reductions in plasma lipid concentrations in pigs.
Ideal Study Design
A double-blind, placebo-controlled RCT in 20+ miniature pigs, randomized to 3 mg/kg/day atorvastatin or placebo for 21 days, with fasting plasma total cholesterol, LDL-C, total triglyceride, and VLDL-TG measured by standardized enzymatic assays as primary endpoints.
Limitation: Cannot determine if lipid changes are due to reduced production, increased clearance, or dietary interactions.
Prospective CohortLevel 2bWhether lipid reductions are dose-dependent or consistent across different diets or pig strains.
Whether lipid reductions are dose-dependent or consistent across different diets or pig strains.
What This Would Prove
Whether lipid reductions are dose-dependent or consistent across different diets or pig strains.
Ideal Study Design
A prospective cohort study following 50 miniature pigs on a standardized high-fat, high-cholesterol diet, with atorvastatin administered at varying doses (0, 1, 3, 5 mg/kg/day) for 21 days, measuring plasma lipid profiles at baseline and endpoint.
Limitation: Cannot establish causation due to lack of randomization and potential confounding by individual variability.
Evidence from Studies
Supporting (1)
Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
The study gave pigs atorvastatin for 21 days while feeding them a fatty diet, and it found exactly the same cholesterol and triglyceride drops as the claim says — so the claim is backed up by the science.